Table 4.

Final coefficient estimates of the likelihood-based boosting model using all clinical and cardiac biomarker data

Variable	Estimated Coefficient
Age, yr	0.391
Non-Hispanic Black race/ethnicity	−0.206
Hispanic race/ethnicity	−0.0492
History of cardiovascular disease	0.0306
History of chronic obstructive pulmonary disease	0.0411
History of myocardial infarction	0.0135
History of peripheral vascular disease	−0.0589
Use of ACEi/ARBs	0.0509
Use of calcium channel blockers	0.00599
Use of diuretics	0.062
Height, cm	0.0686
Weight, kg	0.217
log(NT-proBNP), pg/ml	0.456
log(hsTnT), pg/ml	0.0864

Predicted 5-year risk of atrial fibrillation is 1–${0.9496}^{e^{(\mathrm{\Sigma }X\beta )}}$, where β is the regression coefficient and X is the level for each risk factor listed above. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NT-proBNP, N-terminal pro–B-type natriuretic peptide; hsTnT, high-sensitivity troponin T.